North America Hereditary Cancer Testing Market Size & Outlook
Related Markets
North America hereditary cancer testing market highlights
- The North America hereditary cancer testing market generated a revenue of USD 2,156.5 million in 2024.
- The market is expected to grow at a CAGR of 13.4% from 2025 to 2033.
- In terms of segment, breast cancer was the largest revenue generating cancer in 2024.
- Breast Cancer is the most lucrative cancer segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2025 to 2033.
North America data book summary
| Market revenue in 2024 | USD 2,156.5 million |
| Market revenue in 2033 | USD 6,500.4 million |
| Growth rate | 13.4% (CAGR from 2025 to 2033) |
| Largest segment | Breast cancer |
| Fastest growing segment | Breast Cancer |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Prostate Cancer, Stomach/Gastric Cancer, Melanoma, Sarcoma, Uterine Cancer, Pancreatic Cancer |
| Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Bio-Rad Laboratories Inc, CSL Ltd, Qiagen NV, Danaher Corp, Thermo Fisher Scientific Inc, Abbott Laboratories, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Illumina Inc |
Other key industry trends
- In terms of revenue, North America region accounted for 46.1% of the global hereditary cancer testing market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,577.6 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hereditary Cancer Testing Market Scope
Hereditary Cancer Testing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| CSL Ltd | View profile | 32000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | https://www.csl.com |
| Invitae Corp | View profile | 1700 | 1400 16th Street, San Francisco, CA, United States, 94103 | https://www.invitae.com |
| Myriad Genetics Inc | View profile | 2700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | https://www.myriad.com |
| Eurofins Scientific SE | View profile | 61798 | 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 | https://www.eurofins.com |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Bio-Rad Laboratories Inc | View profile | 8030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | https://www.bio-rad.com |
| Illumina Inc | View profile | 9300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | https://www.illumina.com |
| Danaher Corp | View profile | 63000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | https://www.danaher.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
North America hereditary cancer testing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary cancer testing market will help companies and investors design strategic landscapes.
Breast cancer was the largest segment with a revenue share of 13.77% in 2024. Horizon Databook has segmented the North America hereditary cancer testing market based on lung cancer, breast cancer, colorectal cancer, cervical cancer, ovarian cancer, prostate cancer, stomach/gastric cancer, melanoma, sarcoma, uterine cancer, pancreatic cancer covering the revenue growth of each sub-segment from 2021 to 2033.
North America hereditary cancer testing market dominated the market and accounted for a 46.14% share in 2024. The North American hereditary cancer testing market is experiencing robust growth, driven by advancements in next-generation sequencing (NGS), increasing awareness of genetic risks, and expanded insurance coverage. Technological advancements, including the development of blood-based tests for minimal residual disease detection, are enhancing early diagnosis and personalized treatment strategies.
Collaborations, partnerships are increasing in this region, for example, in October 2023, a rural hospital system in North Carolina demonstrated the clinical benefits of implementing universal hereditary cancer testing for all breast cancer patients conducted in collaboration with Invitae, the study found that 91.4% of patients underwent testing, with 13% identified as carriers of pathogenic germline variants.
Genetic test results informed clinical management decisions in 70% of cases, leading to changes in surgery, radiation, surveillance, and follow-up care. This approach improved patient outcomes and optimized resource utilization, providing a model for integrating genetic testing into rural healthcare settings.
Reasons to subscribe to North America hereditary cancer testing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America hereditary cancer testing market databook
-
Our clientele includes a mix of hereditary cancer testing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America hereditary cancer testing market , including forecasts for subscribers. This continent databook contains high-level insights into North America hereditary cancer testing market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
North America hereditary cancer testing market size, by country, 2021-2033 (US$M)
North America Hereditary Cancer Testing Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
